IP Library Granted Patent US 11,883,371
Granted Patent B2
US 11,883,371 · App. 17/210,205 · Granted Jan 30, 2024

Stress test and treatment of chronic kidney disease

Inventors: Donald Jeffrey Keyser (Southlake, TX); Alvaro F. Guillem (Lantana, TX); Bhupinder Singh (Phoenix, AZ); Richard A. Zager (Seattle, WA)
Assignee: Renibus Therapeutics, Inc.
A61K31/12G01N33/6893G01N2800/7009
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,883,371
App. No.
17/210,205
Granted
Jan 30, 2024
Kind
B2
Abstract

The present invention involves a novel method for treatment of chronic kidney disease comprising administering a compound that induces a stress protein response in a patient, and administering a potent antioxidant if the patent's response is below a predefined level. It also involves a quantitative measure for determining a patient's antioxidant reserve capacity.

Claims (12)

1. A method for treating a patient at risk for having suffered kidney injury or kidney disease progression comprising:

(a) administering a compound to the patient, wherein the compound is a protoporphyrin or mesoporphyrin;

(b) measuring the response of the patient to the compound, wherein the response comprises increased level of expression of one or more anti-oxidant proteins; and

(c) administering a therapy to the patient if the level of expression of the one or more anti-oxidant proteins is above a predefined level.

2. The method of claim 1 , wherein the anti-oxidant proteins comprise one or more of HO-1, ferritin, p21, or NQO1.

3. The method of claim 1 , wherein the level of expression of the one or more anti-oxidant proteins is measured before step (a), and the level of expression of the one or more anti-oxidant proteins measured in step (b) is compared to the level of expression measured before step (a).

4. The method of claim 1 , wherein the patient is suffering from chronic kidney disease.

5. The method of claim 1 , wherein compound is a metal protoporphyrin.

6. The method of claim 5 , wherein the metal protoporphyrin is tin, cobalt, or zinc protoporphyrin.

7. The method claim 1 , wherein the dose of the compound is 9 mg or greater.

8. The method of claim 1 , wherein the therapy comprises administering a potent antioxidant.

9. The method of claim 1 , wherein the therapy comprises administering tetrahydrocurcumen.

Assignments (2)
SECURITY INTEREST Recorded Jun 4, 2026
From: RENIBUS THERAPEUTICS, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
Reel/Frame 074858/0020 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2021
From: KEYSER, DONALD JEFFREY; GUILLEM, ALVARO F.; SINGH, BHUPINDER; ZAGER, RICHARD A.
To: RENIBUS THERAPEUTICS, INC.
Reel/Frame 057130/0549 →
Continuity (2)
Provisional Application 62993446 · Mar 23, 2020
Related Publication 20210322340A1 · Oct 21, 2021